Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 239

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study

Open access
Dispenzieri, Angela, Kyle, Robert A., Lacy, Martha Q., Therneau, Terry M., Larson, Dirk R., Plevak, Matthew F., Rajkumar, S. Vincent, Fonseca, Rafael, Greipp, Philip R., Witzig, Thomas E., Lust, John A., Zeldenrust, Steven R., Snow, Denise S., Hayman, Susan R., Litzow, Mark R., Gastineau, Dennis A., Tefferi, Ayalew, Inwards, David J., Micallef, Ivana N., Ansell, Stephen M., Porrata, Luis F., Elliott, Michelle A., Gertz, Morie A. · 2004 · Blood

Abstract

Primary systemic amyloidosis (AL) is a plasma cell dyscrasia resulting in multisystem failure and death. High-dose chemotherapy with peripheral blood stem cell transplantation (PBSCT) has been associated with higher response rates and seemingly higher overall survival than standard chemotherapy. Selection bias, however, confounds interpretation of these results. We performed a case-match-control study comparing overall survival of 63 AL patients undergoing transplantation with 63 patients not undergoing transplantation. Matching criteria included age, sex, time to presentation, left ventricular ejection fraction, serum creatinine, septal thickness, nerve involvement, 24-hour urine protein, and serum alkaline phosphatase. According to design, there was no difference between the groups with respect to sex (57% males), age (median, 53 years), left ventricular ejection fraction (65%), number of patients with peripheral nerve involvement (17%), cardiac interventricular septal wall thickness (12 mm), serum creatinine (1.1 mg/dL [97.24 μmol/L]), and bone marrow plasmacytosis (8%). Sixty-six patients have died (16 cases and 50 controls). For PBSCT and control groups, respectively, the 1-, 2-, and 4-year overall survival rates are 89% and 71%; 81% and 55%; and 71% and 41%. Outside a randomized clinical trial, these results present the strongest data supporting the role of PBSCT in selected patients with AL.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood-2003-12-4192

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 239

Metadata

Authors
Dispenzieri, A., Kyle, R. A., Lacy, M. Q., Therneau, T. M., Larson, D. R., Plevak, M. F., Rajkumar, S. V., Fonseca, R., Greipp, P. R., Witzig, T. E., Lust, J. A., Zeldenrust, S. R., Snow, D. S., Hayman, S. R., Litzow, M. R., Gastineau, D. A., Tefferi, A., Inwards, D. J., Micallef, I. N., Ansell, S. M., Porrata, L. F., Elliott, M. A., & Gertz, M. A.
Venue
Blood
Published
2004-05-15
Volume
103
Issue
10
Pages
3960-3963
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W2168613652
Cited by
239
References
1
FWCI
8.20
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study. https://app.cochat.ai/papers/10.1182/blood-2003-12-4192
The paper
Dispenzieri, A., Kyle, R. A., Lacy, M. Q., Therneau, T. M., Larson, D. R., Plevak, M. F., Rajkumar, S. V., Fonseca, R., Greipp, P. R., Witzig, T. E., Lust, J. A., Zeldenrust, S. R., Snow, D. S., Hayman, S. R., Litzow, M. R., Gastineau, D. A., Tefferi, A., Inwards, D. J., Micallef, I. N., . . . Gertz, M. A. (2004). Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study. Blood. https://doi.org/10.1182/blood-2003-12-4192

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.